Jonathan B. Wade, PhD

Eli Lilly and Company

Principal Research Scientist

Dr. Wade earned his BSc degree in Medicinal and Pharmaceutical Chemistry from Loughborough University, UK, MSc degree in Pharmaceutical Technology and Ph.D. in Pharmaceutical Science, both from King’s College London, UK. He has over 20 years’ experience across late stage product development, scale up, technology transfer, process validation for both batch and continuous manufacturing process, with a focus in solid oral dosage forms. He has extensive hands on experience authoring, reviewing and approving process validation packages associated with new product introductions, technology transfers and periodic re-validations for legacy products. Currently he is leading commercialization efforts for batch and continuously manufactured drug products across Eli Lilly’s global network.

Features

Process Validation - Small-Molecule Drug Substance & Drug Product Continuous Manufacturing Processes

1 May 2019

Continuous manufacturing (CM) technologies have recently been implemented in the pharmaceutical industry for process development, clinical trials, and commercial supply. This article is a high-level summary of a recently published

Jonathan B. Wade, PhD

Related Articles